- Tags: AMD
Research
Study: MacTel prevalence climbing faster than AMD
Prevalence nearly doubled between 2015 and 2024, with the rate of increase outpacing AMD and diagnoses most common among adults ages 65 to 74.Pipeline
i-Lumen reports new i-SIGHT data on retinal bioelectric stimulation for dry AMD
Expanded clinical findings from U.S.-based feasibility trial include a ≥10-ETDRS letter improvement among over 50% of treated patients.Business
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3B
Pending transaction includes phase 3 funding for OLN324, an investigational bispecific antibody under evaluation for wet AMD and DME.Business
IMVIONIX debuts with acquisition of BEOVU's North American rights
Biotech company launches to commercial space; secures U.S. and Canadian exclusive rights to the FDA-approved injection for wet AMD and DME.Pipeline
EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout
LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.Pipeline
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation
Company reports a constructive meeting with the FDA over a planned trial evaluating oral tonabersat; currently eyeing a 2027 timeframe for kickoff.Pipeline
Merck releases phase 2b/3 DME data for tri-specific antibody
Topline data demonstrates non-inferiority and higher rates of two AEs and treatment discontinuation due to AEs.Pipeline
Kodiak's tarcocimab meets wet AMD phase 3 endpoint, targets Q4 BLA
Zenkuda and KSI-501 both met the primary endpoint in DAYBREAK study, accelerating Kodiak’s development plans.Pipeline
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI
Company remains on track for a Q4 2026 submission; wet AMD IVT implant has the potential for long-term durability and fewer injections.Pipeline
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy
EYC-0305 is under evaluation as a potential long-acting treatment designed for 6-month or longer dosing intervals via IVT injection.Pipeline
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.Research
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.Research
NSAID use may lower AMD risk
Prescribed patients appear less likely for disease development, with the association observed across multiple AMD subtypes and several commonly used medicationsPipeline
4DMT reports new phase 2b gene therapy data for wet AMD
New 2-year data demonstrates an overall 78% treatment reduction in patients treated with 4D-150 compared to bimonthly 2 mg aflibercept.Products
Biocon launches Eylea biosimilar to US market
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.Research
Adverum reports 5-year extension data on wet AMD gene therapy
At ASRS 2026, the OPTIC extension finds a single Ixo-vec injection led to a 87% cumulative reduction in annualized anti-VEGF injections.Products
FDA approves Outlook's LYTENAVA for wet AMD
The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.Research
Mediterranean diet linked to slower AMD progression
Diet aherence associated with slower AMD progression at every disease stage, with specific food components mattering most depending on the stage.Research
New SYFOVRE data extend GA benefit to patients with concurrent wet AMD
SYFOVRE demonstrates reduced photoreceptor and RPE loss in GA patients and those with concomitant nAMD.Pipeline